
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4685331/publications.pdf Version: 2024-02-01



μις ζοςτλ

#	Article	IF	CITATIONS
1	MicroRNAâ€181a restricts human γδT cell differentiation by targeting Map3k2 and Notch2. EMBO Reports, 2022, 23, e52234.	2.0	5
2	Laparoscopic Vena Cava Thrombectomy and Radical Nephrectomy in a Malignant Pheochromocytoma Case. Acta Urológica Portuguesa, 2022, 37, 27-31.	0.1	0
3	Predictive and Therapeutic Implications of a Novel PLCÎ ³ 1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer. Clinical Cancer Research, 2022, 28, 1203-1216.	3.2	7
4	Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning. Oncotarget, 2022, 13, 237-256.	0.8	2
5	A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases. Cancers, 2022, 14, 893.	1.7	2
6	Code of practice needed for samples donated by trial participants. Lancet Oncology, The, 2022, 23, e89-e90.	5.1	4
7	Bone Health in Metastatic Cancer. Seminars in Oncology Nursing, 2022, 38, 151278.	0.7	4
8	Lupin Protein Concentrate as a Novel Functional Food Additive That Can Reduce Colitis-Induced Inflammation and Oxidative Stress. Nutrients, 2022, 14, 2102.	1.7	4
9	Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC Journal of Clinical Oncology, 2022, 40, 9067-9067.	0.8	1
10	Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial Journal of Clinical Oncology, 2022, 40, 107-107.	0.8	6
11	HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome. Npj Genomic Medicine, 2021, 6, 13.	1.7	17
12	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. European Journal of Cancer, 2021, 144, 351-359.	1.3	2
13	Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. Targeted Oncology, 2021, 16, 357-367.	1.7	13
14	Circulating tumor cell detection methods in renal cell carcinoma: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 161, 103331.	2.0	15
15	The Roadmap of RANKL/RANK Pathway in Cancer. Cells, 2021, 10, 1978.	1.8	29
16	Prostate Ewing Sarcoma/PNET: A case of long survival in a highly aggressive malignancy. Urology, 2021, 154, e11-e12.	0.5	4
17	Dynamic modeling of bone remodeling, osteolytic metastasis and PK/PD therapy: introducing variable order derivatives as a simplification technique. Journal of Mathematical Biology, 2021, 83, 39.	0.8	1
18	HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device. Cancers, 2021, 13, 4446.	1.7	22

#	Article	IF	CITATIONS
19	Immunotherapy in Metastatic Mucosal Melanoma with Disseminated Intravascular Coagulation: A Case of Success. Case Reports in Immunology, 2021, 2021, 1-5.	0.2	3
20	c-Met expression in renal cell carcinoma with bone metastases. Journal of Bone Oncology, 2020, 25, 100315.	1.0	10
21	Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma. Reports of Practical Oncology and Radiotherapy, 2020, 25, 768-774.	0.3	7
22	Bone metastases. Nature Reviews Disease Primers, 2020, 6, 83.	18.1	246
23	Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases. Cancers, 2020, 12, 2034.	1.7	5
24	Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. Targeted Oncology, 2020, 15, 301-315.	1.7	37
25	Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic. Annals of Allergy, Asthma and Immunology, 2020, 125, 325-333.e1.	0.5	28
26	Prognostic factors for patients treated with abiraterone. Future Science OA, 2020, 6, FSO436.	0.9	4
27	Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis. Cancer and Metastasis Reviews, 2020, 39, 603-623.	2.7	50
28	Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer. Oncotarget, 2020, 11, 1714-1728.	0.8	15
29	360 Health Analysis (H360) – A Proposal for an Integrated Vision of Breast Cancer in Portugal. The Journal of Breast Health, 2020, 16, 91-98.	0.4	2
30	Low doses of ionizing radiation activate endothelial cells and induce angiogenesis in peritumoral tissues. Radiotherapy and Oncology, 2019, 141, 256-261.	0.3	11
31	Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study. Clinical Breast Cancer, 2019, 19, e654-e667.	1.1	4
32	Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancerâ€induced bone loss. British Journal of Clinical Pharmacology, 2019, 85, 1114-1124.	1.1	21
33	Modelling cancer outcomes of bone metastatic patients: combining survival data with N-Telopeptide of type I collagen (NTX) dynamics through joint models. BMC Medical Informatics and Decision Making, 2019, 19, 13.	1.5	3
34	Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treatment Reviews, 2019, 76, 57-67.	3.4	85
35	Cancer Treatment-Induced Bone Loss (CTIBL). , 2019, , 296-303.		1
36	Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases. International Journal of Molecular Sciences, 2019, 20, 695.	1.8	18

LUIS COSTA

#	Article	IF	CITATIONS
37	Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Scientific Reports, 2019, 9, 19761.	1.6	41
38	Bone Metastasis. , 2019, , 1115-1137.		0
39	Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study. Breast, 2018, 37, 107-113.	0.9	6
40	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. Advances in Experimental Medicine and Biology, 2018, 1110, 113-131.	0.8	19
41	Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. Advances in Experimental Medicine and Biology, 2018, 1096, 117-133.	0.8	58
42	Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. European Journal of Cancer, 2017, 71, 80-94.	1.3	74
43	Adjuvant zoledronic acid to treat breast cancer: not for all. Lancet Oncology, The, 2017, 18, 1437-1439.	5.1	4
44	Radionuclides in oncology clinical practice – review of the literature. Dalton Transactions, 2017, 46, 14475-14487.	1.6	4
45	Bone metastasis risk factors in breast cancer. Ecancermedicalscience, 2017, 11, 715.	0.6	79
46	Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry Journal of Clinical Oncology, 2017, 35, 212-212.	0.8	3
47	Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry Journal of Clinical Oncology, 2017, 35, 5028-5028.	0.8	1
48	Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry Journal of Clinical Oncology, 2017, 35, e16537-e16537.	0.8	0
49	Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?. International Journal of Molecular Sciences, 2016, 17, 1415.	1.8	35
50	N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases. Oncologist, 2016, 21, 1418-1426.	1.9	17
51	Organização e implementação de uma consulta de cardioâ€oncologia. Revista Portuguesa De Cardiologia, 2016, 35, 485-494.	0.2	9
52	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study. Breast, 2016, 29, 68-73.	0.9	8
53	Dynamic modeling of bone metastasis, microenvironment and therapy. Journal of Theoretical Biology, 2016, 391, 1-12.	0.8	19
54	Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer. Clinical Colorectal Cancer, 2016, 15, 170-178.e3.	1.0	70

#	Article	IF	CITATIONS
55	Health resource utilization associated with skeletal-related events: results from a retrospective European study. European Journal of Health Economics, 2016, 17, 711-721.	1.4	16
56	The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?. Journal of Clinical Oncology, 2016, 34, 5024-5024.	0.8	0
57	Low Molecular Weight Protein Tyrosine Phosphatase Slow Isoform Knockdown in MDA-MB-435 Cells Decreases RAW 264.7 Osteoclastic Differentiation. Anticancer Research, 2016, 36, 2227-32.	O.5	2
58	Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors. BioMed Research International, 2015, 2015, 1-7.	0.9	6
59	Targeting bone metastases in prostate cancer: improving clinical outcome. Nature Reviews Urology, 2015, 12, 340-356.	1.9	87
60	The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review. Breast Cancer Research, 2015, 17, 140.	2.2	143
61	Bone remodeling markers and bone metastases: From cancer research to clinical implications. BoneKEy Reports, 2015, 4, 668.	2.7	45
62	Bone Metastases. , 2015, , 867-889.		0
63	Which bisphosphonate to treat bone metastases?. Lancet Oncology, The, 2014, 15, 15-16.	5.1	8
64	Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Supportive Care in Cancer, 2014, 22, 679-687.	1.0	146
65	New Targeted Therapies for Bone Metastases. Cancer Metastasis - Biology and Treatment, 2014, , 235-246.	0.1	Ο
66	Biological assessment of novel bisphosphonate-containing 99mTc/Re-organometallic complexes. Journal of Organometallic Chemistry, 2014, 760, 197-204.	0.8	14
67	The global cancer genomics consortium's third annual symposium: from oncogenomics to cancer care. Genes and Cancer, 2014, 5, 64-70.	0.6	1
68	Treatment of bone metastases before the onset of pain. International Journal of Clinical Oncology, 2013, 18, 531-538.	1.0	17
69	Carboplatin-, Oxaliplatin-, and Cisplatin–specific IgE: Cross-reactivity and Value in the Diagnosis of Carboplatin and Oxaliplatin Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 494-500.	2.0	75
70	Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing. Scientific Reports, 2013, 3, 2256.	1.6	63
71	Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2013, 2, 70-76.	1.0	34
72	The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis. Tumor Biology, 2013, 34, 1979-1989.	0.8	23

LUIS COSTA

#	Article	IF	CITATIONS
73	MTA1 Promotes STAT3 Transcription and Pulmonary Metastasis in Breast Cancer. Cancer Research, 2013, 73, 3761-3770.	0.4	61
74	RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro. PLoS ONE, 2013, 8, e63153.	1.1	66
75	The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012. ISRN Hepatology, 2013, 2013, 1-9.	0.9	4
76	Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases Journal of Clinical Oncology, 2013, 31, 5079-5079.	0.8	2
77	Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism. PLoS ONE, 2013, 8, e76307.	1.1	9
78	N-telopeptide of type I collagen (NTX) dynamics over one year of determinations in patients with breast cancer (BC) with bone metastases (BM): Predictive factors of outcome Journal of Clinical Oncology, 2013, 31, 9634-9634.	0.8	0
79	Characterization of low molecular weight protein tyrosine phosphatase isoforms in human breast cancer epithelial cell lines. Anticancer Research, 2013, 33, 1983-7.	0.5	5
80	Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. OncoTargets and Therapy, 2012, 5, 409.	1.0	14
81	Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment. Prostate Cancer, 2012, 2012, 1-11.	0.4	79
82	Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations. Cancer Treatment Reviews, 2012, 38, 815-824.	3.4	15
83	Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated?. Breast Cancer Research and Treatment, 2012, 134, 453-457.	1.1	10
84	Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clinical and Experimental Metastasis, 2012, 29, 155-164.	1.7	41
85	Elevated pretreatment serum activinÂA and progression-free and overall survival in trastuzumab-treated metastatic breast cancer Journal of Clinical Oncology, 2012, 30, 607-607.	0.8	0
86	Elevated pretreatment serum activinÂA and progression-free and overall survival in trastuzumab-treated metastatic breast cancer Journal of Clinical Oncology, 2012, 30, 38-38.	0.8	0
87	Lactoferrin–Endothelin-1 Axis Contributes to the Development and Invasiveness of Triple-Negative Breast Cancer Phenotypes. Cancer Research, 2011, 71, 7259-7269.	0.4	36
88	Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Journal of Clinical Oncology, 2011, 29, 1125-1132.	0.8	1,090
89	Bone turnover markers: Tools for prognosis and monitoring response to bisphosphonates?. Breast Disease, 2011, 33, 59-69.	0.4	14
90	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	2.0	84

#	Article	IF	CITATIONS
91	Anticancer evidence for zoledronic acid across the cancer continuum. Critical Reviews in Oncology/Hematology, 2011, 77, S31-S37.	2.0	25
92	Reply to S.M. Sorscher et al. Journal of Clinical Oncology, 2011, 29, 2736-2737.	0.8	2
93	Phase I Trial of Zoledronic Acid + Imatinib Mesylate (Gleevec) in Patients With Bone Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 75-78.	0.6	9
94	Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 2010, 123, 767-779.	1.1	62
95	Zoledronic Acid: Its Use in the Treatment of Breast Cancer. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2353.	0.4	0
96	Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases. Oncologist, 2010, 15, 1147-1158.	1.9	42
97	Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nature Reviews Clinical Oncology, 2009, 6, 163-174.	12.5	136
98	^{99m} Tc-Tricarbonyl Complexes Functionalized with Anthracenyl Fragments: Synthesis, Characterization, and Evaluation of Their Radiotoxic Effects in Murine Melanoma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 551-563.	0.7	24
99	Bone Metastases From Advanced Cancers. Clinical Journal of Oncology Nursing, 2009, 13, 701-710.	0.3	13
100	Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Supportive Care in Cancer, 2008, 16, 879-889.	1.0	175
101	Role of Bisphosphonates for the Management of Skeletal Complications and Bone Pain from Skeletal Metastases. Supportive Cancer Therapy, 2006, 3, 143-153.	0.3	25
102	Biochemical Markers and Skeletal Metastases. Clinical Orthopaedics and Related Research, 2003, 415, S138-S147.	0.7	32
103	Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status. Journal of Clinical Oncology, 2002, 20, 850-856.	0.8	176
104	Biochemical markers and skeletal metastases. Cancer, 2000, 88, 2919-2926.	2.0	169
105	The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. Oncotarget, 0, 7, 41380-41389.	0.8	7
106	Exploring new pathways in endocrine-resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 337-361.	0.5	2